SlideShare una empresa de Scribd logo
1 de 56
PRESENTED BY
DR SHASHANK AGRAWAL
(MEDICINE)
 Glomerular disease includes
glomerulonephritis, i.e. inflammation of the
glomeruli and glomerulopathies when there
is no evidence of inflammation.
 Glomerulonephritis is a subset of
glomerulopathies
 Nephrotic syndrome.
 Acute glomerulonephritis (acute nephritic
syndrome).
 Rapidly progressive glomerulonephritis.
 Asymptomatic urinary abnormality
(haematuria, proteinuria or both).
Primary – confined to the kidney
Secondary – due to a systemic
disease
5
 Proteinuria – asymptomatic
 Haematuria – asymptomatic
 Hypertension
 Nephrotic syndrome
 Nephritic syndrome
 Acute renal failure
 Rapidly progressive renal failure
 End stage renal failure
6
 Presence of glomerular disease as opposed to
tubulointersititial or vascular disease is suspected from
history
 Haematuria (especially dysmorphic red cells)
 Red cell casts
 Lipiduria (glomerular permeability must be increased to
allow the filtration of large lipoproteins)
 Proteinuria (may be in nephrotic range of >3.5 g/24hours)
Immune complex disease
 Neutrophils:
Protease GBM degradation
O₂ free readicals cell damage
AA metabolites ↓ GFR
Complement- dependentComplement-leukocyte- mediated
mechanism
 Activation of the complement
pathway Recruitment of neutrophils
and monocytes
C₅- C₉ (MAC)
Epithelial cell detachment.
 (+) epithelial & mesangial
cells to secrete damaging
chemical mediators.
Upregulates TGF receptors on
epithelial cells, excessive
synthesis of extracellular matrix
which leads to GBM
thickening
 Named according to
 etiology
 microscopic findings
 clinical syndrome
 Most common clinical presentations
 acute nephritic syndrome
 nephrotic syndrome
 Most common cause is autoimmune
 Autoimmune injury initiated by beta-hemolytic
streptococcus
 aka acute proliferative glomerulonephritis
 Presents as acute nephritic syndrome
 hematuria
 HT
 increased urea & creatinine
 low urine output
 edema
 Antibodies produced by strep throat deposit in glomerulus
 Most fully recover but about 10% evolve into rapidly
progressive glomerulonephritis
 Unknown causes or secondary to
poststreptococcal
glomerulonephritis
 Autoimmune
 aka crescentric
glomerulonephritis
 Some present as acute nephritic
syndrome & others as renal
failure
 Caused by deposition of An-Ab
complexes
 All but a few progress to renal
failure
 Autoimmune
 Most common cause of
nephrotic syndrome in
adults
 About 10% proceed to
renal failure within 10
yrs, 25% recover
completely, most
progress slowly with
proteinuria, HTN, loss
of renal function
 Incidental discovery of occult proteinuria or
HTN
 Usually presents as chronic renal failure or
occult proteinuria
 Glomerulus has scar tissue
 Dialysis & transplant
 Diabetes most common cause
 most common cause of renal failure
 glycoproteins deposit in basement membrane
 Vascular disease
 atherosclerosis
 HTN
 vascultitis
Heavy
proteinuria
Proteinuria &
haematuria
Predominant
haematuria
Minimal Change Lupus nephritis Acute post strep
Focal sclerosis
Membranous
Diabetes Mellitus
Amyloidosis
Membrano-
proliferative
Endocarditis
Henoch-Schonlein
purpura
Crescentic
(RPGN)
Haemolytic
uraemic syndrome
 Acute glomerulonephritis is the
inflammation of the glomeruli which causes
the kidneys to malfunction
 It is also called Acute Nephritis,
Glomerulonephritis and Post-Streptococcal
Glomerulonephritis
 Predominantly affects children from ages 2
to 12
 Incubation period is 2 to 3 weeks
 Infectious
 Streptococcal
 Nonstreptococcal postinfectious
glomerulonephritis
▪ Bacterial
▪ Viral
▪ Parasitic
 Noninfectious
 Multisystem systemic diseases
 Primary glomerular diseases
Previously M-protein of the organism was
felt to be responsible for PSGN.
Recently, nephritis-associated
streptococcal cationic protease and its
zymogen precursor (NAPR) has been
identified as a glyceraldehyde-3-phosphate
dehydrogenase that functions as a
plasmin(ogen) receptor.
Diffuse proliferative GN (PGN)
 proliferation of cells within the glomeruli, accompanied
by leukocyte filtrate
 typical features of immune complex disease :
- hypocomplimentemia
- granular deposits of IgG & complement on GBM
 Implicated antigens seem to be endostreptosin and nephritis –
plasmin- binding ptn
 Fever
 Headache
 Malaise
 Anorexia
 Nausea and vomiting
 High blood pressure
 Pallor due to edema and/or anemia
 Confusion
 Lethargy
 Loss of muscle tissue
 Enlargement of the liver
 Hematuria: dark brown or smoky urine
 Oliguria: urine output is < 400 ml/day
 Edema: starts in the eye lids and face then
the lower and upper limbs then becomes
generalized; may be migratory
 Hypertension: usually mild to moderate
 urinary (haematuria, proteinuria),
 nephritic (edemas, hypertension, gross
haematuria, proteinuria),
 nephrotic (edemas, proteinuria,
hypoproteinemia, hypercholesterolemia),
 mixed.
 Abrupt onset of:
glomerular haematuria (RBC
casts or dysmorphic RBC).
non-nephrotic range
proteinuria (<2 g in 24 hrs).
oedema (periorbital, sacral).
hypertension.
transient renal impairment
(oliguria, uraemia).
Base line measurements:
- ↑ Urea
- ↑ Creatinine
Urinalysis (MSU):
a) Urine microscopy (red cell cast)
b) proteinuria
COMPLICATION
Hypertensive encephalopathy, heart failure and acute
pulmonary edema may occur in severe cases
Acute renal necrosis due to injury of capillary or capillary
thrombosis
Treat the underlying infections when acute GN is associated with chronic infections.
 Antimicrobial therapy
 Antibiotics (eg, penicillin) are used to control local symptoms and to prevent
spread of infection to close contacts.
 Antimicrobial therapy does not appear to prevent the development of GN,
except if given within the first 36 hours.
 Loop diuretic therapy
 Loop diuretics may be required in patients who are edematous and hypertensive
in order to remove excess fluid and to correct hypertension.
 Relieves edema and controls volume, thereby helping to control volume-related
elevation in BP.
 Vasodilator drugs (eg, nitroprusside, nifedipine, hydralazine, diazoxide) may be
used if severe hypertension or encephalopathy is present
 Diet:
 Sodium and fluid restriction
 Protein restriction for azotemic patients
 Activity: Recommend bed rest until signs of glomerular inflammation and
circulatory congestion subside.
Post streptococcal GN
- Has a GOOD prognosis.
- Supportive measures until spontaneous recovery.
- Control HT.
- Fluid balance.
- Oliguric with fluid overload.
- GN complicating SLE or systemic vasculitides:
immunosuppression with prednisolone,
cyclophosphamide or azathioprine/MMF.
The condition is characterized by
irreversible and progressive glomerular and
tubulointerstitial fibrosis.
-> ultimately leading to a reduction in the
glomerular filtration rate (GFR) and retention
of uremic toxins.
-> If disease progression is not halted with
therapy, the net result is chronic kidney
disease (CKD), end-stage renal disease
(ESRD), and cardiovascular disease
Nearly all forms of acute glomerulonephritis have a
tendency to progress to chronic glomerulonephritis.
The progression from acute glomerulonephritis to
chronic glomerulonephritis is variable.
Whereas complete recovery of renal function is the
rule for patients with poststreptococcal
glomerulonephritis, several other
glomerulonephritides, such as immunoglobulin A
(IgA) nephropathy, often have a relatively benign
course and many do not progress to ESRD.
Reduction in nephron mass from the initial injury
reduces the GFR.
This reduction leads to hypertrophy and
hyperfiltration of the remaining nephrons and to the
initiation of intraglomerular hypertension.
These changes occur in order to increase the GFR of
the remaining nephrons, thus minimizing the
functional consequences of nephron loss.
The changes, however, are ultimately detrimental
because they lead to glomerulosclerosis and further
nephron loss.
fusion of podocytes
on electron microscopy
Segmental areas of
glomerular sclerosis,
hyalinization of
glomerular capillaries
large glomeruli with mesangial
proliferation and ‘double’ BM. 2 histological
types: type I (subendothelial deposits) type II
(intramembranous deposits)
thickened BM, IF +ve
for IgG & C3 and
subepithelial deposits
on EM
Hypercellularity, mesangial proliferation,
inflammatory cell infiltrate, positive IF for IgG
and C3 and subepithelial deposits on EM.
 Most common cause of GN in Asia but uncommon in Sth
America or Africa
 15-40% of all biopsy proven GN
 Male > Females
 2nd
-3rd
decade
 Most commonly asymptomatic with serendipitous finding of
haematuria and mild proteinuria
 Another classic presentation is macroscopic haematuria in
conjunction with a viral infection
 Renal function is usually normal but occasionally a patient
will present with acute renal failure due to acute tubular
necrosis secondary to the gross haematuria
 Biopsy – mild to moderate mesangial cell proliferation, IgA
deposits in the mesangium on immunofluorescence, often
with C3 deposition also
 Slowly progressive
 By 20 years, 50% have end stage kidney
disease
 Worse prognosis if >1g/day proteinuria,
hypertension, increased creatinine of
glomerular fibrosis at biopsy, on presentation
 Uremia-specific findings
 Edemas
 Hypertension
 Jugular venous distension (if severe volume overload is
present)
 Pulmonary rales (if pulmonary edema is present)
 Pericardial friction rub in pericarditis
 Tenderness in the epigastric region or blood in the stool
(possible indicators for uremic gastritis or enteropathy)
 Decreased sensation and asterixis (indicators for advanced
uremia)
 Latent (changes in urine)
 Hypertensive (increased blood pressure)
 Hematuric
 Nephrotic (edemas, proteinuria,
hypoproteinemia, hypercholesterolemia),
 Mixed
 Urinalysis
 Urinary protein excretion
 Serum chemistry
 Serum creatinine and urea nitrogen levels are elevated.
 Impaired excretion of potassium, free water, and acid results
in hyperkalemia, hyponatremia, and low serum bicarbonate
levels, respectively.
 Impaired vitamin D-3 production results in hypocalcemia,
hyperphosphatemia, and high levels of parathyroid
hormone.
 Low serum albumin levels may be present if uremia
interferes with nutrition or if the patient is nephrotic.
 Renal ultrasonogram
 Obtain a renal ultrasonogram to determine renal
size, to assess for the presence of both kidneys,
and to exclude structural lesions that may be
responsible for azotemia.
 Small kidneys often indicate an irreversible
process.
 Kidney biopsy
 The target pressure for patients with proteinuria greater
than 1 g/d is less than 125/75 mm Hg; for patients with
proteinuria less than 1 g/d, the target pressure is less than
130/80 mm Hg.
 Angiotensin-converting enzyme inhibitors (ACEIs)
 angiotensin II receptor blockers (ARBs)
 combination therapy with ACEIs and ARBs.
 Diuretics
 Beta-blockers,
 calcium channel blockers,
 central alpha-2 agonists (eg, clonidine),
 alpha-1 antagonists
 direct vasodilators (eg, minoxidil, nitrates) may be used to achieve
the target pressure.
 Renal osteodystrophy can be managed early by
replacing vitamin D and by administering phosphate
binders.
 Seek and treat nonuremic causes of anemia, such as
iron deficiency, before instituting therapy with
erythropoietin.
 Discuss options for renal replacement therapy (eg,
hemodialysis, peritoneal dialysis, renal
transplantation).
 Treat hyperlipidemia (if present)
 Expose patients to educational programs for early
rehabilitation from dialysis or transplantation.
Minimal change glomerulonephritis (MCGN)
Corticosteroids induce remission in >90% of
children and 80% of adults (slower response).
Indications for immunosuppression:
(cyclophosphamide, ciclosporin (=cylosporin)):
early/ frequent relapses; steroid SEs/dependence.
Prognosis: 1% progress to ESRF.
Focal segmental glomerulosclerosis
Poor response to corticosteroids (10–30%).
Cyclophosphamide or ciclosporin
(=cylosporin) may be used in steroid-resistant
cases.
Prognosis: 30–50% progress to ESRF.
Mesangiocapillary GN
Treatment: None is of proven benefit.
Prognosis: 50% develop ESRF.
Membranous nephropathy
If renal function deteriorates, consider
corticosteroids and chlorambucil.
Prognosis: Untreated, 15% complete
remission, 9% ESRF at 2–5yrs and 41% at
15yrs.
Mesangial proliferative GN
Antibiotics, diuretics, and
antihypertensives as necessary. Dialysis is
rarely required.
Prognosis: Good.
 Management
 Aggressive control of blood pressure and
proteinuria with ACEI’s or AR2B’s
 Corticosteroids +/- azathiprine – varied schools of
thought
 However if rapidly progressive GN with crescent
deposition treatment should be aggressive with
high dose steroids and cyclophosphamide
 Consult the Nephrologist
Rapidly progressive glomerulonephritis
(RPGN) is a disease of the kidney that results
in a rapid decrease in the glomerular filtration
rate of at least 50% over a short period, from
a few days to 3 months.
50
 Classic – haemoptysis after upper respiratory infection and
have nephritic urinary sediment
 History of smoking or hydrocarbon exposure is common
 CXR – pulmonary haemorrhage
 Lab- iron deficiency anaemia and renal dysfunction,
circulating anti-GBM antibodies
 Kidney biopsy crescentic GN with linear staining IgG and C3
along the glomerular basement membrane
More than 80% of patients with
pauci-immune RPGN were
subsequently found to have
circulating antineutrophil
cytoplasmic antibodies (ANCA),
and thus, this form of RPGN is now
termed ANCA-associated vasculitis.
RPGN is classified pathologically into 3
categories:
 (1) anti-GBM antibody disease
(approximately 3% of cases),
 (2) immune complex disease (45% of cases),
 (3) pauci-immune disease (50% of cases).
 Symptoms and signs of renal failure,
 pain,
 haematuria,
 systemic symptoms (fever, malaise, myalgia,
weight loss).
 The most important requirement in the diagnosis of antineutrophil
cytoplasmic antibodies (ANCA) ANCA-associated disease is a high index
of suspicion. Rapid diagnosis is essential for organ preservation.
Laboratory studies include the following:
 Routine chemistry: The most common
abnormality is an increased serum
creatinine level.
 Urinalysis with microscopy:
 Antinuclear antibody (ANA) titer:
 ANCA .
High-dose corticosteroids;
cyclophosphamide ± plasma exchange/ renal
transplantation. Prognosis: Poor if initial
serum creatinine >600µmol/L.
THANK YOU

Más contenido relacionado

La actualidad más candente

Management Of Nephrotic Syndrome
Management Of Nephrotic SyndromeManagement Of Nephrotic Syndrome
Management Of Nephrotic SyndromeNaveen Kumar Cheri
 
Nephrotic Syndrome
Nephrotic SyndromeNephrotic Syndrome
Nephrotic SyndromeCSN Vittal
 
Post streptococcal glomerulonephritis
Post streptococcal glomerulonephritis Post streptococcal glomerulonephritis
Post streptococcal glomerulonephritis Praveen RK
 
Glomerulonephritis
GlomerulonephritisGlomerulonephritis
GlomerulonephritisHari Nagar
 
Chronic pyelonephritis
Chronic pyelonephritisChronic pyelonephritis
Chronic pyelonephritisLaya Pillai
 
NEPHRITIC SYNDROME / APSGN IN CHILDREN
NEPHRITIC SYNDROME / APSGN IN CHILDREN NEPHRITIC SYNDROME / APSGN IN CHILDREN
NEPHRITIC SYNDROME / APSGN IN CHILDREN Sajjad Sabir
 
Chronic glomerulonephritis
Chronic glomerulonephritisChronic glomerulonephritis
Chronic glomerulonephritisArsenic Halcyon
 
Nephritic syndrome renal pathology- prof wadie
Nephritic syndrome   renal pathology- prof wadieNephritic syndrome   renal pathology- prof wadie
Nephritic syndrome renal pathology- prof wadieMohamed Wadie
 
Nephrotic And Nephritic Syndrome 2008
Nephrotic And Nephritic Syndrome 2008Nephrotic And Nephritic Syndrome 2008
Nephrotic And Nephritic Syndrome 2008Dang Thanh Tuan
 
Acute pyelonephritis
Acute pyelonephritisAcute pyelonephritis
Acute pyelonephritisMahesh Chand
 
Overview of management of nephrotic syndrom
Overview of management of nephrotic syndromOverview of management of nephrotic syndrom
Overview of management of nephrotic syndromOgechukwu Uzoamaka Mbanu
 
Acute glomerulonephritis (agn)
Acute glomerulonephritis (agn)Acute glomerulonephritis (agn)
Acute glomerulonephritis (agn)Yogesh Dengale
 
Membranous glomerulonephritis
Membranous glomerulonephritisMembranous glomerulonephritis
Membranous glomerulonephritisMohammad Manzoor
 

La actualidad más candente (20)

Management Of Nephrotic Syndrome
Management Of Nephrotic SyndromeManagement Of Nephrotic Syndrome
Management Of Nephrotic Syndrome
 
Nephrotic Syndrome
Nephrotic SyndromeNephrotic Syndrome
Nephrotic Syndrome
 
Post streptococcal glomerulonephritis
Post streptococcal glomerulonephritis Post streptococcal glomerulonephritis
Post streptococcal glomerulonephritis
 
Glomerulonephritis
GlomerulonephritisGlomerulonephritis
Glomerulonephritis
 
Chronic pyelonephritis
Chronic pyelonephritisChronic pyelonephritis
Chronic pyelonephritis
 
Nephrotic syndrome
Nephrotic syndromeNephrotic syndrome
Nephrotic syndrome
 
NEPHRITIC SYNDROME / APSGN IN CHILDREN
NEPHRITIC SYNDROME / APSGN IN CHILDREN NEPHRITIC SYNDROME / APSGN IN CHILDREN
NEPHRITIC SYNDROME / APSGN IN CHILDREN
 
Nephrotic Syndrome
Nephrotic SyndromeNephrotic Syndrome
Nephrotic Syndrome
 
Chronic glomerulonephritis
Chronic glomerulonephritisChronic glomerulonephritis
Chronic glomerulonephritis
 
Nephritic syndrome renal pathology- prof wadie
Nephritic syndrome   renal pathology- prof wadieNephritic syndrome   renal pathology- prof wadie
Nephritic syndrome renal pathology- prof wadie
 
Acute Kidney Injury
Acute Kidney InjuryAcute Kidney Injury
Acute Kidney Injury
 
Nephrotic And Nephritic Syndrome 2008
Nephrotic And Nephritic Syndrome 2008Nephrotic And Nephritic Syndrome 2008
Nephrotic And Nephritic Syndrome 2008
 
Pyelonephritis
PyelonephritisPyelonephritis
Pyelonephritis
 
Acute pyelonephritis
Acute pyelonephritisAcute pyelonephritis
Acute pyelonephritis
 
NEPHROTIC SYNDROME
NEPHROTIC SYNDROMENEPHROTIC SYNDROME
NEPHROTIC SYNDROME
 
Overview of management of nephrotic syndrom
Overview of management of nephrotic syndromOverview of management of nephrotic syndrom
Overview of management of nephrotic syndrom
 
Diabetic nephropathy
Diabetic nephropathyDiabetic nephropathy
Diabetic nephropathy
 
Glomerular Nephritis
Glomerular NephritisGlomerular Nephritis
Glomerular Nephritis
 
Acute glomerulonephritis (agn)
Acute glomerulonephritis (agn)Acute glomerulonephritis (agn)
Acute glomerulonephritis (agn)
 
Membranous glomerulonephritis
Membranous glomerulonephritisMembranous glomerulonephritis
Membranous glomerulonephritis
 

Similar a Glomerulonephritis (1)

Chronic Glomerulonephritis.pptx
Chronic Glomerulonephritis.pptxChronic Glomerulonephritis.pptx
Chronic Glomerulonephritis.pptxDarshanS239776
 
Acute and Chronic Renal Failure - A Review
Acute and Chronic Renal Failure - A ReviewAcute and Chronic Renal Failure - A Review
Acute and Chronic Renal Failure - A ReviewJoseph A. Di Como MD
 
Acute and chronic glomerulonephritis
Acute and chronic glomerulonephritisAcute and chronic glomerulonephritis
Acute and chronic glomerulonephritisMuzaffarAnnaev
 
Haematuria & Renal Failure
Haematuria & Renal FailureHaematuria & Renal Failure
Haematuria & Renal Failuremimios
 
Chronic renal Disease\failure (CKD)
Chronic renal Disease\failure (CKD)Chronic renal Disease\failure (CKD)
Chronic renal Disease\failure (CKD)Dr.mujahid Abdallah
 
1 curs nefrologie-de prezentat-ii- 23 februariei-2016
1 curs  nefrologie-de prezentat-ii-  23 februariei-20161 curs  nefrologie-de prezentat-ii-  23 februariei-2016
1 curs nefrologie-de prezentat-ii- 23 februariei-2016andrei victor
 
APSGN.pptx
APSGN.pptxAPSGN.pptx
APSGN.pptxgufp
 
GENITO-URINARY SYSTEM DISORDERS PART-1.
GENITO-URINARY SYSTEM DISORDERS PART-1.GENITO-URINARY SYSTEM DISORDERS PART-1.
GENITO-URINARY SYSTEM DISORDERS PART-1.DR .PALLAVI PATHANIA
 
Nephrology 2,09
Nephrology 2,09Nephrology 2,09
Nephrology 2,09Miami Dade
 
Nephrotic presentation.ppt9999999999999999999999999999999999999
Nephrotic presentation.ppt9999999999999999999999999999999999999Nephrotic presentation.ppt9999999999999999999999999999999999999
Nephrotic presentation.ppt9999999999999999999999999999999999999JamesAmaduKamara
 
Glomerular diseases
Glomerular diseasesGlomerular diseases
Glomerular diseasesSujay Iyer
 
Glomerulonephritis nurse teaching jan 2017
Glomerulonephritis nurse teaching jan 2017Glomerulonephritis nurse teaching jan 2017
Glomerulonephritis nurse teaching jan 2017Dr Amber Z Jafferi
 
Nephrotic Syndrome- The mulas-1.ppt
Nephrotic Syndrome- The mulas-1.pptNephrotic Syndrome- The mulas-1.ppt
Nephrotic Syndrome- The mulas-1.pptSharonKabwela
 
glomerulonephritis (5).pptx
glomerulonephritis (5).pptxglomerulonephritis (5).pptx
glomerulonephritis (5).pptxfaisaliqbal142
 

Similar a Glomerulonephritis (1) (20)

Chronic Glomerulonephritis.pptx
Chronic Glomerulonephritis.pptxChronic Glomerulonephritis.pptx
Chronic Glomerulonephritis.pptx
 
Acute and Chronic Renal Failure - A Review
Acute and Chronic Renal Failure - A ReviewAcute and Chronic Renal Failure - A Review
Acute and Chronic Renal Failure - A Review
 
Acute and chronic glomerulonephritis
Acute and chronic glomerulonephritisAcute and chronic glomerulonephritis
Acute and chronic glomerulonephritis
 
Glomerulonephritis
GlomerulonephritisGlomerulonephritis
Glomerulonephritis
 
Haematuria & Renal Failure
Haematuria & Renal FailureHaematuria & Renal Failure
Haematuria & Renal Failure
 
Proteinuria & Hematuria
Proteinuria & HematuriaProteinuria & Hematuria
Proteinuria & Hematuria
 
Chronic renal Disease\failure (CKD)
Chronic renal Disease\failure (CKD)Chronic renal Disease\failure (CKD)
Chronic renal Disease\failure (CKD)
 
Renal Failure.ppt
Renal Failure.pptRenal Failure.ppt
Renal Failure.ppt
 
1 curs nefrologie-de prezentat-ii- 23 februariei-2016
1 curs  nefrologie-de prezentat-ii-  23 februariei-20161 curs  nefrologie-de prezentat-ii-  23 februariei-2016
1 curs nefrologie-de prezentat-ii- 23 februariei-2016
 
APSGN.pptx
APSGN.pptxAPSGN.pptx
APSGN.pptx
 
GENITO-URINARY SYSTEM DISORDERS PART-1.
GENITO-URINARY SYSTEM DISORDERS PART-1.GENITO-URINARY SYSTEM DISORDERS PART-1.
GENITO-URINARY SYSTEM DISORDERS PART-1.
 
Nephrology 2,09
Nephrology 2,09Nephrology 2,09
Nephrology 2,09
 
Nephrotic presentation.ppt9999999999999999999999999999999999999
Nephrotic presentation.ppt9999999999999999999999999999999999999Nephrotic presentation.ppt9999999999999999999999999999999999999
Nephrotic presentation.ppt9999999999999999999999999999999999999
 
Glomerular diseases
Glomerular diseasesGlomerular diseases
Glomerular diseases
 
Glomerular diseases
Glomerular diseasesGlomerular diseases
Glomerular diseases
 
Glomerulonephritis nurse teaching jan 2017
Glomerulonephritis nurse teaching jan 2017Glomerulonephritis nurse teaching jan 2017
Glomerulonephritis nurse teaching jan 2017
 
Nephrotic Syndrome- The mulas-1.ppt
Nephrotic Syndrome- The mulas-1.pptNephrotic Syndrome- The mulas-1.ppt
Nephrotic Syndrome- The mulas-1.ppt
 
Renal function test
Renal function testRenal function test
Renal function test
 
Common urinary symptom
Common urinary symptomCommon urinary symptom
Common urinary symptom
 
glomerulonephritis (5).pptx
glomerulonephritis (5).pptxglomerulonephritis (5).pptx
glomerulonephritis (5).pptx
 

Más de shashank agrawal

Más de shashank agrawal (6)

Hypertension diagnosis and management
Hypertension diagnosis and managementHypertension diagnosis and management
Hypertension diagnosis and management
 
Septic shock management (1)
Septic shock management (1)Septic shock management (1)
Septic shock management (1)
 
Renal replacement therapy_
Renal replacement therapy_Renal replacement therapy_
Renal replacement therapy_
 
Hiv.ppt
Hiv.pptHiv.ppt
Hiv.ppt
 
chronic kidney disease.ppt
chronic kidney disease.pptchronic kidney disease.ppt
chronic kidney disease.ppt
 
Abdominal examination
Abdominal examinationAbdominal examination
Abdominal examination
 

Último

Call Girls in Munirka Delhi 💯Call Us 🔝8264348440🔝
Call Girls in Munirka Delhi 💯Call Us 🔝8264348440🔝Call Girls in Munirka Delhi 💯Call Us 🔝8264348440🔝
Call Girls in Munirka Delhi 💯Call Us 🔝8264348440🔝soniya singh
 
OECD bibliometric indicators: Selected highlights, April 2024
OECD bibliometric indicators: Selected highlights, April 2024OECD bibliometric indicators: Selected highlights, April 2024
OECD bibliometric indicators: Selected highlights, April 2024innovationoecd
 
User Guide: Capricorn FLX™ Weather Station
User Guide: Capricorn FLX™ Weather StationUser Guide: Capricorn FLX™ Weather Station
User Guide: Capricorn FLX™ Weather StationColumbia Weather Systems
 
Forensic limnology of diatoms by Sanjai.pptx
Forensic limnology of diatoms by Sanjai.pptxForensic limnology of diatoms by Sanjai.pptx
Forensic limnology of diatoms by Sanjai.pptxkumarsanjai28051
 
basic entomology with insect anatomy and taxonomy
basic entomology with insect anatomy and taxonomybasic entomology with insect anatomy and taxonomy
basic entomology with insect anatomy and taxonomyDrAnita Sharma
 
ALL ABOUT MIXTURES IN GRADE 7 CLASS PPTX
ALL ABOUT MIXTURES IN GRADE 7 CLASS PPTXALL ABOUT MIXTURES IN GRADE 7 CLASS PPTX
ALL ABOUT MIXTURES IN GRADE 7 CLASS PPTXDole Philippines School
 
ECG Graph Monitoring with AD8232 ECG Sensor & Arduino.pptx
ECG Graph Monitoring with AD8232 ECG Sensor & Arduino.pptxECG Graph Monitoring with AD8232 ECG Sensor & Arduino.pptx
ECG Graph Monitoring with AD8232 ECG Sensor & Arduino.pptxmaryFF1
 
Harmful and Useful Microorganisms Presentation
Harmful and Useful Microorganisms PresentationHarmful and Useful Microorganisms Presentation
Harmful and Useful Microorganisms Presentationtahreemzahra82
 
GenBio2 - Lesson 1 - Introduction to Genetics.pptx
GenBio2 - Lesson 1 - Introduction to Genetics.pptxGenBio2 - Lesson 1 - Introduction to Genetics.pptx
GenBio2 - Lesson 1 - Introduction to Genetics.pptxBerniceCayabyab1
 
Topic 9- General Principles of International Law.pptx
Topic 9- General Principles of International Law.pptxTopic 9- General Principles of International Law.pptx
Topic 9- General Principles of International Law.pptxJorenAcuavera1
 
Four Spheres of the Earth Presentation.ppt
Four Spheres of the Earth Presentation.pptFour Spheres of the Earth Presentation.ppt
Four Spheres of the Earth Presentation.pptJoemSTuliba
 
STOPPED FLOW METHOD & APPLICATION MURUGAVENI B.pptx
STOPPED FLOW METHOD & APPLICATION MURUGAVENI B.pptxSTOPPED FLOW METHOD & APPLICATION MURUGAVENI B.pptx
STOPPED FLOW METHOD & APPLICATION MURUGAVENI B.pptxMurugaveni B
 
Behavioral Disorder: Schizophrenia & it's Case Study.pdf
Behavioral Disorder: Schizophrenia & it's Case Study.pdfBehavioral Disorder: Schizophrenia & it's Case Study.pdf
Behavioral Disorder: Schizophrenia & it's Case Study.pdfSELF-EXPLANATORY
 
The dark energy paradox leads to a new structure of spacetime.pptx
The dark energy paradox leads to a new structure of spacetime.pptxThe dark energy paradox leads to a new structure of spacetime.pptx
The dark energy paradox leads to a new structure of spacetime.pptxEran Akiva Sinbar
 
FREE NURSING BUNDLE FOR NURSES.PDF by na
FREE NURSING BUNDLE FOR NURSES.PDF by naFREE NURSING BUNDLE FOR NURSES.PDF by na
FREE NURSING BUNDLE FOR NURSES.PDF by naJASISJULIANOELYNV
 
Pests of safflower_Binomics_Identification_Dr.UPR.pdf
Pests of safflower_Binomics_Identification_Dr.UPR.pdfPests of safflower_Binomics_Identification_Dr.UPR.pdf
Pests of safflower_Binomics_Identification_Dr.UPR.pdfPirithiRaju
 
《Queensland毕业文凭-昆士兰大学毕业证成绩单》
《Queensland毕业文凭-昆士兰大学毕业证成绩单》《Queensland毕业文凭-昆士兰大学毕业证成绩单》
《Queensland毕业文凭-昆士兰大学毕业证成绩单》rnrncn29
 
REVISTA DE BIOLOGIA E CIÊNCIAS DA TERRA ISSN 1519-5228 - Artigo_Bioterra_V24_...
REVISTA DE BIOLOGIA E CIÊNCIAS DA TERRA ISSN 1519-5228 - Artigo_Bioterra_V24_...REVISTA DE BIOLOGIA E CIÊNCIAS DA TERRA ISSN 1519-5228 - Artigo_Bioterra_V24_...
REVISTA DE BIOLOGIA E CIÊNCIAS DA TERRA ISSN 1519-5228 - Artigo_Bioterra_V24_...Universidade Federal de Sergipe - UFS
 
Vision and reflection on Mining Software Repositories research in 2024
Vision and reflection on Mining Software Repositories research in 2024Vision and reflection on Mining Software Repositories research in 2024
Vision and reflection on Mining Software Repositories research in 2024AyushiRastogi48
 

Último (20)

Call Girls in Munirka Delhi 💯Call Us 🔝8264348440🔝
Call Girls in Munirka Delhi 💯Call Us 🔝8264348440🔝Call Girls in Munirka Delhi 💯Call Us 🔝8264348440🔝
Call Girls in Munirka Delhi 💯Call Us 🔝8264348440🔝
 
OECD bibliometric indicators: Selected highlights, April 2024
OECD bibliometric indicators: Selected highlights, April 2024OECD bibliometric indicators: Selected highlights, April 2024
OECD bibliometric indicators: Selected highlights, April 2024
 
User Guide: Capricorn FLX™ Weather Station
User Guide: Capricorn FLX™ Weather StationUser Guide: Capricorn FLX™ Weather Station
User Guide: Capricorn FLX™ Weather Station
 
Forensic limnology of diatoms by Sanjai.pptx
Forensic limnology of diatoms by Sanjai.pptxForensic limnology of diatoms by Sanjai.pptx
Forensic limnology of diatoms by Sanjai.pptx
 
basic entomology with insect anatomy and taxonomy
basic entomology with insect anatomy and taxonomybasic entomology with insect anatomy and taxonomy
basic entomology with insect anatomy and taxonomy
 
ALL ABOUT MIXTURES IN GRADE 7 CLASS PPTX
ALL ABOUT MIXTURES IN GRADE 7 CLASS PPTXALL ABOUT MIXTURES IN GRADE 7 CLASS PPTX
ALL ABOUT MIXTURES IN GRADE 7 CLASS PPTX
 
ECG Graph Monitoring with AD8232 ECG Sensor & Arduino.pptx
ECG Graph Monitoring with AD8232 ECG Sensor & Arduino.pptxECG Graph Monitoring with AD8232 ECG Sensor & Arduino.pptx
ECG Graph Monitoring with AD8232 ECG Sensor & Arduino.pptx
 
Harmful and Useful Microorganisms Presentation
Harmful and Useful Microorganisms PresentationHarmful and Useful Microorganisms Presentation
Harmful and Useful Microorganisms Presentation
 
GenBio2 - Lesson 1 - Introduction to Genetics.pptx
GenBio2 - Lesson 1 - Introduction to Genetics.pptxGenBio2 - Lesson 1 - Introduction to Genetics.pptx
GenBio2 - Lesson 1 - Introduction to Genetics.pptx
 
Topic 9- General Principles of International Law.pptx
Topic 9- General Principles of International Law.pptxTopic 9- General Principles of International Law.pptx
Topic 9- General Principles of International Law.pptx
 
Volatile Oils Pharmacognosy And Phytochemistry -I
Volatile Oils Pharmacognosy And Phytochemistry -IVolatile Oils Pharmacognosy And Phytochemistry -I
Volatile Oils Pharmacognosy And Phytochemistry -I
 
Four Spheres of the Earth Presentation.ppt
Four Spheres of the Earth Presentation.pptFour Spheres of the Earth Presentation.ppt
Four Spheres of the Earth Presentation.ppt
 
STOPPED FLOW METHOD & APPLICATION MURUGAVENI B.pptx
STOPPED FLOW METHOD & APPLICATION MURUGAVENI B.pptxSTOPPED FLOW METHOD & APPLICATION MURUGAVENI B.pptx
STOPPED FLOW METHOD & APPLICATION MURUGAVENI B.pptx
 
Behavioral Disorder: Schizophrenia & it's Case Study.pdf
Behavioral Disorder: Schizophrenia & it's Case Study.pdfBehavioral Disorder: Schizophrenia & it's Case Study.pdf
Behavioral Disorder: Schizophrenia & it's Case Study.pdf
 
The dark energy paradox leads to a new structure of spacetime.pptx
The dark energy paradox leads to a new structure of spacetime.pptxThe dark energy paradox leads to a new structure of spacetime.pptx
The dark energy paradox leads to a new structure of spacetime.pptx
 
FREE NURSING BUNDLE FOR NURSES.PDF by na
FREE NURSING BUNDLE FOR NURSES.PDF by naFREE NURSING BUNDLE FOR NURSES.PDF by na
FREE NURSING BUNDLE FOR NURSES.PDF by na
 
Pests of safflower_Binomics_Identification_Dr.UPR.pdf
Pests of safflower_Binomics_Identification_Dr.UPR.pdfPests of safflower_Binomics_Identification_Dr.UPR.pdf
Pests of safflower_Binomics_Identification_Dr.UPR.pdf
 
《Queensland毕业文凭-昆士兰大学毕业证成绩单》
《Queensland毕业文凭-昆士兰大学毕业证成绩单》《Queensland毕业文凭-昆士兰大学毕业证成绩单》
《Queensland毕业文凭-昆士兰大学毕业证成绩单》
 
REVISTA DE BIOLOGIA E CIÊNCIAS DA TERRA ISSN 1519-5228 - Artigo_Bioterra_V24_...
REVISTA DE BIOLOGIA E CIÊNCIAS DA TERRA ISSN 1519-5228 - Artigo_Bioterra_V24_...REVISTA DE BIOLOGIA E CIÊNCIAS DA TERRA ISSN 1519-5228 - Artigo_Bioterra_V24_...
REVISTA DE BIOLOGIA E CIÊNCIAS DA TERRA ISSN 1519-5228 - Artigo_Bioterra_V24_...
 
Vision and reflection on Mining Software Repositories research in 2024
Vision and reflection on Mining Software Repositories research in 2024Vision and reflection on Mining Software Repositories research in 2024
Vision and reflection on Mining Software Repositories research in 2024
 

Glomerulonephritis (1)

  • 1. PRESENTED BY DR SHASHANK AGRAWAL (MEDICINE)
  • 2.  Glomerular disease includes glomerulonephritis, i.e. inflammation of the glomeruli and glomerulopathies when there is no evidence of inflammation.  Glomerulonephritis is a subset of glomerulopathies
  • 3.  Nephrotic syndrome.  Acute glomerulonephritis (acute nephritic syndrome).  Rapidly progressive glomerulonephritis.  Asymptomatic urinary abnormality (haematuria, proteinuria or both).
  • 4. Primary – confined to the kidney Secondary – due to a systemic disease
  • 5. 5  Proteinuria – asymptomatic  Haematuria – asymptomatic  Hypertension  Nephrotic syndrome  Nephritic syndrome  Acute renal failure  Rapidly progressive renal failure  End stage renal failure
  • 6. 6  Presence of glomerular disease as opposed to tubulointersititial or vascular disease is suspected from history  Haematuria (especially dysmorphic red cells)  Red cell casts  Lipiduria (glomerular permeability must be increased to allow the filtration of large lipoproteins)  Proteinuria (may be in nephrotic range of >3.5 g/24hours)
  • 7.
  • 8. Immune complex disease  Neutrophils: Protease GBM degradation O₂ free readicals cell damage AA metabolites ↓ GFR Complement- dependentComplement-leukocyte- mediated mechanism  Activation of the complement pathway Recruitment of neutrophils and monocytes C₅- C₉ (MAC) Epithelial cell detachment.  (+) epithelial & mesangial cells to secrete damaging chemical mediators. Upregulates TGF receptors on epithelial cells, excessive synthesis of extracellular matrix which leads to GBM thickening
  • 9.  Named according to  etiology  microscopic findings  clinical syndrome  Most common clinical presentations  acute nephritic syndrome  nephrotic syndrome  Most common cause is autoimmune
  • 10.  Autoimmune injury initiated by beta-hemolytic streptococcus  aka acute proliferative glomerulonephritis  Presents as acute nephritic syndrome  hematuria  HT  increased urea & creatinine  low urine output  edema  Antibodies produced by strep throat deposit in glomerulus  Most fully recover but about 10% evolve into rapidly progressive glomerulonephritis
  • 11.  Unknown causes or secondary to poststreptococcal glomerulonephritis  Autoimmune  aka crescentric glomerulonephritis  Some present as acute nephritic syndrome & others as renal failure  Caused by deposition of An-Ab complexes  All but a few progress to renal failure
  • 12.  Autoimmune  Most common cause of nephrotic syndrome in adults  About 10% proceed to renal failure within 10 yrs, 25% recover completely, most progress slowly with proteinuria, HTN, loss of renal function
  • 13.  Incidental discovery of occult proteinuria or HTN  Usually presents as chronic renal failure or occult proteinuria  Glomerulus has scar tissue  Dialysis & transplant
  • 14.  Diabetes most common cause  most common cause of renal failure  glycoproteins deposit in basement membrane  Vascular disease  atherosclerosis  HTN  vascultitis
  • 15. Heavy proteinuria Proteinuria & haematuria Predominant haematuria Minimal Change Lupus nephritis Acute post strep Focal sclerosis Membranous Diabetes Mellitus Amyloidosis Membrano- proliferative Endocarditis Henoch-Schonlein purpura Crescentic (RPGN) Haemolytic uraemic syndrome
  • 16.  Acute glomerulonephritis is the inflammation of the glomeruli which causes the kidneys to malfunction  It is also called Acute Nephritis, Glomerulonephritis and Post-Streptococcal Glomerulonephritis  Predominantly affects children from ages 2 to 12  Incubation period is 2 to 3 weeks
  • 17.  Infectious  Streptococcal  Nonstreptococcal postinfectious glomerulonephritis ▪ Bacterial ▪ Viral ▪ Parasitic  Noninfectious  Multisystem systemic diseases  Primary glomerular diseases
  • 18. Previously M-protein of the organism was felt to be responsible for PSGN. Recently, nephritis-associated streptococcal cationic protease and its zymogen precursor (NAPR) has been identified as a glyceraldehyde-3-phosphate dehydrogenase that functions as a plasmin(ogen) receptor.
  • 19. Diffuse proliferative GN (PGN)  proliferation of cells within the glomeruli, accompanied by leukocyte filtrate  typical features of immune complex disease : - hypocomplimentemia - granular deposits of IgG & complement on GBM  Implicated antigens seem to be endostreptosin and nephritis – plasmin- binding ptn
  • 20.  Fever  Headache  Malaise  Anorexia  Nausea and vomiting  High blood pressure  Pallor due to edema and/or anemia  Confusion  Lethargy  Loss of muscle tissue  Enlargement of the liver
  • 21.  Hematuria: dark brown or smoky urine  Oliguria: urine output is < 400 ml/day  Edema: starts in the eye lids and face then the lower and upper limbs then becomes generalized; may be migratory  Hypertension: usually mild to moderate
  • 22.  urinary (haematuria, proteinuria),  nephritic (edemas, hypertension, gross haematuria, proteinuria),  nephrotic (edemas, proteinuria, hypoproteinemia, hypercholesterolemia),  mixed.
  • 23.  Abrupt onset of: glomerular haematuria (RBC casts or dysmorphic RBC). non-nephrotic range proteinuria (<2 g in 24 hrs). oedema (periorbital, sacral). hypertension. transient renal impairment (oliguria, uraemia).
  • 24. Base line measurements: - ↑ Urea - ↑ Creatinine Urinalysis (MSU): a) Urine microscopy (red cell cast) b) proteinuria COMPLICATION Hypertensive encephalopathy, heart failure and acute pulmonary edema may occur in severe cases Acute renal necrosis due to injury of capillary or capillary thrombosis
  • 25. Treat the underlying infections when acute GN is associated with chronic infections.  Antimicrobial therapy  Antibiotics (eg, penicillin) are used to control local symptoms and to prevent spread of infection to close contacts.  Antimicrobial therapy does not appear to prevent the development of GN, except if given within the first 36 hours.  Loop diuretic therapy  Loop diuretics may be required in patients who are edematous and hypertensive in order to remove excess fluid and to correct hypertension.  Relieves edema and controls volume, thereby helping to control volume-related elevation in BP.  Vasodilator drugs (eg, nitroprusside, nifedipine, hydralazine, diazoxide) may be used if severe hypertension or encephalopathy is present  Diet:  Sodium and fluid restriction  Protein restriction for azotemic patients  Activity: Recommend bed rest until signs of glomerular inflammation and circulatory congestion subside.
  • 26. Post streptococcal GN - Has a GOOD prognosis. - Supportive measures until spontaneous recovery. - Control HT. - Fluid balance. - Oliguric with fluid overload. - GN complicating SLE or systemic vasculitides: immunosuppression with prednisolone, cyclophosphamide or azathioprine/MMF.
  • 27. The condition is characterized by irreversible and progressive glomerular and tubulointerstitial fibrosis. -> ultimately leading to a reduction in the glomerular filtration rate (GFR) and retention of uremic toxins. -> If disease progression is not halted with therapy, the net result is chronic kidney disease (CKD), end-stage renal disease (ESRD), and cardiovascular disease
  • 28. Nearly all forms of acute glomerulonephritis have a tendency to progress to chronic glomerulonephritis. The progression from acute glomerulonephritis to chronic glomerulonephritis is variable. Whereas complete recovery of renal function is the rule for patients with poststreptococcal glomerulonephritis, several other glomerulonephritides, such as immunoglobulin A (IgA) nephropathy, often have a relatively benign course and many do not progress to ESRD.
  • 29. Reduction in nephron mass from the initial injury reduces the GFR. This reduction leads to hypertrophy and hyperfiltration of the remaining nephrons and to the initiation of intraglomerular hypertension. These changes occur in order to increase the GFR of the remaining nephrons, thus minimizing the functional consequences of nephron loss. The changes, however, are ultimately detrimental because they lead to glomerulosclerosis and further nephron loss.
  • 30. fusion of podocytes on electron microscopy
  • 31. Segmental areas of glomerular sclerosis, hyalinization of glomerular capillaries
  • 32. large glomeruli with mesangial proliferation and ‘double’ BM. 2 histological types: type I (subendothelial deposits) type II (intramembranous deposits)
  • 33. thickened BM, IF +ve for IgG & C3 and subepithelial deposits on EM
  • 34. Hypercellularity, mesangial proliferation, inflammatory cell infiltrate, positive IF for IgG and C3 and subepithelial deposits on EM.
  • 35.  Most common cause of GN in Asia but uncommon in Sth America or Africa  15-40% of all biopsy proven GN  Male > Females  2nd -3rd decade  Most commonly asymptomatic with serendipitous finding of haematuria and mild proteinuria  Another classic presentation is macroscopic haematuria in conjunction with a viral infection  Renal function is usually normal but occasionally a patient will present with acute renal failure due to acute tubular necrosis secondary to the gross haematuria  Biopsy – mild to moderate mesangial cell proliferation, IgA deposits in the mesangium on immunofluorescence, often with C3 deposition also
  • 36.  Slowly progressive  By 20 years, 50% have end stage kidney disease  Worse prognosis if >1g/day proteinuria, hypertension, increased creatinine of glomerular fibrosis at biopsy, on presentation
  • 37.  Uremia-specific findings  Edemas  Hypertension  Jugular venous distension (if severe volume overload is present)  Pulmonary rales (if pulmonary edema is present)  Pericardial friction rub in pericarditis  Tenderness in the epigastric region or blood in the stool (possible indicators for uremic gastritis or enteropathy)  Decreased sensation and asterixis (indicators for advanced uremia)
  • 38.  Latent (changes in urine)  Hypertensive (increased blood pressure)  Hematuric  Nephrotic (edemas, proteinuria, hypoproteinemia, hypercholesterolemia),  Mixed
  • 39.  Urinalysis  Urinary protein excretion  Serum chemistry  Serum creatinine and urea nitrogen levels are elevated.  Impaired excretion of potassium, free water, and acid results in hyperkalemia, hyponatremia, and low serum bicarbonate levels, respectively.  Impaired vitamin D-3 production results in hypocalcemia, hyperphosphatemia, and high levels of parathyroid hormone.  Low serum albumin levels may be present if uremia interferes with nutrition or if the patient is nephrotic.
  • 40.  Renal ultrasonogram  Obtain a renal ultrasonogram to determine renal size, to assess for the presence of both kidneys, and to exclude structural lesions that may be responsible for azotemia.  Small kidneys often indicate an irreversible process.  Kidney biopsy
  • 41.  The target pressure for patients with proteinuria greater than 1 g/d is less than 125/75 mm Hg; for patients with proteinuria less than 1 g/d, the target pressure is less than 130/80 mm Hg.  Angiotensin-converting enzyme inhibitors (ACEIs)  angiotensin II receptor blockers (ARBs)  combination therapy with ACEIs and ARBs.  Diuretics  Beta-blockers,  calcium channel blockers,  central alpha-2 agonists (eg, clonidine),  alpha-1 antagonists  direct vasodilators (eg, minoxidil, nitrates) may be used to achieve the target pressure.
  • 42.  Renal osteodystrophy can be managed early by replacing vitamin D and by administering phosphate binders.  Seek and treat nonuremic causes of anemia, such as iron deficiency, before instituting therapy with erythropoietin.  Discuss options for renal replacement therapy (eg, hemodialysis, peritoneal dialysis, renal transplantation).  Treat hyperlipidemia (if present)  Expose patients to educational programs for early rehabilitation from dialysis or transplantation.
  • 43. Minimal change glomerulonephritis (MCGN) Corticosteroids induce remission in >90% of children and 80% of adults (slower response). Indications for immunosuppression: (cyclophosphamide, ciclosporin (=cylosporin)): early/ frequent relapses; steroid SEs/dependence. Prognosis: 1% progress to ESRF.
  • 44. Focal segmental glomerulosclerosis Poor response to corticosteroids (10–30%). Cyclophosphamide or ciclosporin (=cylosporin) may be used in steroid-resistant cases. Prognosis: 30–50% progress to ESRF.
  • 45. Mesangiocapillary GN Treatment: None is of proven benefit. Prognosis: 50% develop ESRF.
  • 46. Membranous nephropathy If renal function deteriorates, consider corticosteroids and chlorambucil. Prognosis: Untreated, 15% complete remission, 9% ESRF at 2–5yrs and 41% at 15yrs.
  • 47. Mesangial proliferative GN Antibiotics, diuretics, and antihypertensives as necessary. Dialysis is rarely required. Prognosis: Good.
  • 48.  Management  Aggressive control of blood pressure and proteinuria with ACEI’s or AR2B’s  Corticosteroids +/- azathiprine – varied schools of thought  However if rapidly progressive GN with crescent deposition treatment should be aggressive with high dose steroids and cyclophosphamide  Consult the Nephrologist
  • 49. Rapidly progressive glomerulonephritis (RPGN) is a disease of the kidney that results in a rapid decrease in the glomerular filtration rate of at least 50% over a short period, from a few days to 3 months.
  • 50. 50  Classic – haemoptysis after upper respiratory infection and have nephritic urinary sediment  History of smoking or hydrocarbon exposure is common  CXR – pulmonary haemorrhage  Lab- iron deficiency anaemia and renal dysfunction, circulating anti-GBM antibodies  Kidney biopsy crescentic GN with linear staining IgG and C3 along the glomerular basement membrane
  • 51. More than 80% of patients with pauci-immune RPGN were subsequently found to have circulating antineutrophil cytoplasmic antibodies (ANCA), and thus, this form of RPGN is now termed ANCA-associated vasculitis.
  • 52. RPGN is classified pathologically into 3 categories:  (1) anti-GBM antibody disease (approximately 3% of cases),  (2) immune complex disease (45% of cases),  (3) pauci-immune disease (50% of cases).
  • 53.  Symptoms and signs of renal failure,  pain,  haematuria,  systemic symptoms (fever, malaise, myalgia, weight loss).
  • 54.  The most important requirement in the diagnosis of antineutrophil cytoplasmic antibodies (ANCA) ANCA-associated disease is a high index of suspicion. Rapid diagnosis is essential for organ preservation. Laboratory studies include the following:  Routine chemistry: The most common abnormality is an increased serum creatinine level.  Urinalysis with microscopy:  Antinuclear antibody (ANA) titer:  ANCA .
  • 55. High-dose corticosteroids; cyclophosphamide ± plasma exchange/ renal transplantation. Prognosis: Poor if initial serum creatinine >600µmol/L.